RE: Completely out21 Nov 2020 14:44
Dallo – I think you’re a priori reasoning is right. We know that Cephalon exercised its rights in 2009 to take the worldwide rights to Lupuzor for $45m paid plus milestone payments estimated at $500m, plus royalties. (It was when (and because) these paid-for rights reverted to IMM for free in 2011 that I first invested in IMM.). I think Lupuzor’s credentials have improved since and, so far as I understand, it not lost place to any competitor solutions. So this empirical evidence (albeit 11 years-old) suggests your a priori valuation is modest to say the least.
In other words, this is more likely than not a multi bagger sharpish.